Gerresheimer (ETR:GXI) PT Set at €61.00 by JPMorgan Chase & Co.

Gerresheimer (ETR:GXI) has been assigned a €61.00 ($70.93) price objective by equities researchers at JPMorgan Chase & Co. in a report issued on Wednesday, October 23rd, Borsen Zeitung reports. The firm presently has a “neutral” rating on the stock. JPMorgan Chase & Co.‘s target price would suggest a potential downside of 16.78% from the stock’s current price.

Several other research firms have also issued reports on GXI. HSBC set a €85.00 ($98.84) price objective on Gerresheimer and gave the stock a “buy” rating in a research note on Monday, October 14th. Hauck & Aufhaeuser set a €50.00 ($58.14) target price on Gerresheimer and gave the stock a “sell” rating in a report on Thursday, October 10th. DZ Bank restated a “neutral” rating on shares of Gerresheimer in a report on Friday, October 11th. Deutsche Bank set a €83.00 ($96.51) price target on Gerresheimer and gave the company a “buy” rating in a report on Monday, October 14th. Finally, Goldman Sachs Group set a €65.00 ($75.58) price target on Gerresheimer and gave the company a “neutral” rating in a report on Thursday, October 10th. Two analysts have rated the stock with a sell rating, four have assigned a hold rating and four have issued a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and a consensus target price of €71.44 ($83.07).

Shares of GXI stock traded up €0.05 ($0.06) during trading hours on Wednesday, reaching €73.30 ($85.23). 51,232 shares of the company’s stock were exchanged, compared to its average volume of 140,925. The company has a quick ratio of 0.54, a current ratio of 0.81 and a debt-to-equity ratio of 65.99. The business has a fifty day moving average price of €67.93 and a 200-day moving average price of €67.66. Gerresheimer has a fifty-two week low of €51.10 ($59.42) and a fifty-two week high of €74.80 ($86.98). The stock has a market capitalization of $2.30 billion and a P/E ratio of 11.11.

About Gerresheimer

Gerresheimer AG manufactures and sells specialty glass and plastic products primarily for the pharma and healthcare industry worldwide. It operates through three divisions; Plastics & Devices, Primary Packaging Glass, and Advanced Technologies. The Plastics & Devices division offers drug delivery systems, including inhalers, pen systems, and injection systems; sterile and non-sterile prefillable syringe systems for the pharmaceutical and biotech industries; and disposables for various analysis systems that are used in laboratories and medical practices, quick tests for patients in medical practices or hospitals, skin-prick aids and lancets for diabetics, disposables and components for dialysis machines, and catheters and surgical devices.

Featured Article: Cost of Goods Sold (COGS)

Analyst Recommendations for Gerresheimer (ETR:GXI)

Receive News & Ratings for Gerresheimer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gerresheimer and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News